Carl P. Sherr & Co. LLC Sells 556 Shares of Eli Lilly and Company (NYSE:LLY)

Carl P. Sherr & Co. LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,317 shares of the company’s stock after selling 556 shares during the period. Eli Lilly and Company accounts for about 1.9% of Carl P. Sherr & Co. LLC’s portfolio, making the stock its 10th biggest position. Carl P. Sherr & Co. LLC’s holdings in Eli Lilly and Company were worth $3,099,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Simon Quick Advisors LLC increased its stake in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $363,000. WASHINGTON TRUST Co raised its holdings in Eli Lilly and Company by 16.5% in the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares during the period. Liontrust Investment Partners LLP acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $8,326,000. Finally, Redhawk Wealth Advisors Inc. increased its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after buying an additional 65 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 0.5 %

NYSE LLY traded down $4.03 during trading hours on Wednesday, hitting $746.74. 2,569,799 shares of the company traded hands, compared to its average volume of 2,215,511. The stock has a market capitalization of $709.52 billion, a price-to-earnings ratio of 128.75, a P/E/G ratio of 1.64 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The business’s 50-day moving average is $763.51 and its 200-day moving average is $657.01. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Finally, Truist Financial reiterated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.